.png){kind=icon}
.png){kind=icon}
Return
Apolipoprotein E genotyping for pharmacogenetic purposes in Alzheimer's disease: Emerging ethical issues
.png){kind=icon}
OA
AI
DOI：10.1177/070674370004501007.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Objective: To pr-ec ent some of the ethical concerns pertaining to the anticipated use of apolipoprotein E genotyping in selecting therapy in Alzheimer's disease. Method: We, review studies that support the utility of apolipoprotein E (APO E) genotyping for predicting drug responsiveness along,with the published consensus statements and position papers related to APO E genotyping. Ethical issues pertaining to the use of APO E genotyping for pharmacogenetic purposes have not yet been fully explored, and these are discussed. Results: This payer explores the bioethics surrounding the use of APO E genotyping for pharmacogenetic purposes. The rapidly increasing pace of clinical trials in Alzheimer's disease necessitates a critical examination of the evolving ethical issues. A framework for establishing guidelines is suggested Conclusions: Clinical research trials for Alzheimer's disease nifh a genotyping component will increasingly he influenced by and benefit from a serious analysis of the ethics emerging alongside the scientific and clinical advances.
Keywords:
Alzheimer's disease
apolipoprotein E
bioethics
clinical research
genotyping
pharmacogenetics
research ethics
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
C
IF:
3.8
Papers:
7.3K
Citations:
7.6K
Organization
No organization information available